Immunization Newsbriefs (c) Copyright Information Inc.,

Bethesda, MD. Brought to you by the National Network for

Immunization Information (NNii). Visit NNii's new website at

http://www.immunizationinfo.org .

 

------------------------------------------------------------

 

August 16, 2002

 

INTERNATIONAL IMMUNIZATION NEWS

 

"30,000 to Be Tested for BCG Vaccine Potency"

Irish Times ( www.ireland.com ) (08/14/02) P. 3; O'Brien, Tim

 

UK-based vaccine manufacturer Evans Vaccine Ltd. [a subsidiary of

Powderject Pharmaceuticals] is on the hot seat again with the

Irish Medicines Board as the potency of its tuberculosis (TB)

vaccine appears to be inferior.  The board noted, however, that

there are no safety issues with the vaccine, "other than a

possible reduced effectiveness."  Health officials throughout

Ireland are now trying to locate as many as 30,000 people who may

have been vaccinated between April 2000 and April 2002.  Those

identified, most of whom are children and infants, will be called

in to receive a visual test of the slight scar formation which

indicates that the vaccine was effective; if no scarring is

evident, the Mantoux test may be carried out, and repeated if

necessary.  Anyone who still tests negative can be re-vaccinated

with a more potent shot of the BCG vaccine that has been secured

from other sources.  For Evans Vaccines, whose license has now

been suspended by the Irish Medicines Board, this is the second

time in two months that the board has expressed dissatisfaction

with vaccines supplied by the firm.

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.